Baird Maintains Neutral on Beta Bionics, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Neutral 53.8%

Neg 0% Neu 53.8% Pos 0%

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $14 to $16.